Hims' moat is data, not drug dispensing
Paul Serra argued the market is overly focused on Hims & Hers Health's ability to market and dispense drugs, but the real long-term value and defensible moat lies in its ability to collect and utilize patient data to improve retention and lifetime value.
YET ANOTHER VALUE PODCAST CHANGED ITS VIEW
BEARISH FOR 0 DAYS, THEN THE TURNKeep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.